17,261 trials
Melanoma
Primary: Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Drug, Related AEs, Immune-related AEs (IrAEs)…
Male Breast Carcinoma · Recurrent Breast Carcinoma · Stage IV Breast Cancer AJCC v6 and v7
Primary: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) — 2; 1; 1; 0 DLTs
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 88.6; 90.6; 81.8 percentage of participants
Persian Gulf Syndrome
Primary: SF-36P — 73.7; 64.3 units on a scale — p=0.03
Endometrial Adenocarcinoma · Recurrent Endometrial Carcinoma · Stage IV Endometrial Carcinoma
Primary: Tumor Response — 12 percentage of participants
Non-small Cell Lung Cancer
Primary: Tumor Response by Direct RECIST Measurement — 0 participants
Head and Neck Cancer
Primary: Number of Participants Demonstrating the Safety and Tolerability of Long Term Erlotinib Treatment — 26; 22; 22; 6 participants
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients
Malaria
Primary: Number of Subjects Reported With Serious Adverse Events (SAEs) — 5; 4; 5; 7 Participants
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) · Laymen Terminology Chronic Bronchitis and Emphysema
Primary: Patients Who Experienced at Least One Adverse Events(s) — 9; 10; 6 Participants
Kidney Failure · Renal Failure
Primary: Pharmacokinetics of LCP-Tacro™ Tablets in the First 14 Days After Transplantation in Adult de Novo Kidney Recipients. — 78.57; 57.14 percentage of patients
Cystic Fibrosis
Primary: Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) After 2 Weeks of Treatment — 0.5828; 2.0898…
Stage IV Squamous Cell Carcinoma of the Hypopharynx · Stage IV Squamous Cell Carcinoma of the Larynx · Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease) — 2; 9; 2 participants
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Primary: Objective Response Rate Within the First 56 Weeks After the First Dose of Vandetanib — 38.5 percentage of participants
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.8; 4.0; 4.8 months